Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome
A Phase 2 Randomized, Double-Masked Placebo-Controlled Crossover Safety and Tolerability Study of Ataluren for Drug Resistant Epilepsy in Patients With Nonsense Mutation CDKL5 or Dravet Syndrome A Phase 2 Randomized, Double-Masked Placebo-Controlled Crossover Safety and Tolerability Study of At ...